Sarepta Therapeutics, Inc. SRPT Payments to Acquire Debt Securities, Available-for-Sale
Payments to Acquire Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale?
- Sarepta Therapeutics, Inc. (SRPT) reported payments to acquire debt securities, available-for-sale of $170.2M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale changed year-over-year?
- Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale increased by 281.1% year-over-year, from $44.66M to $170.2M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale?
- Over 2 years (2022 to 2024), Sarepta Therapeutics, Inc.'s payments to acquire debt securities, available-for-sale has grown at a -24.7% compound annual growth rate (CAGR), from $1.94B to $1.1B.